Armata Pharmaceuticals, Inc.

NYSE American:ARMP

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 69.85 M

Share Price

USD 1.93

Avg Daily Volume

246,065

Change (1 day)

1.05%

Change (1 year)

-31.80%

Change (YTD)

4.32%

Armata Pharmaceuticals, Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: 4.32%

Armata Pharmaceuticals, Inc. Share Price Year-To-Date (YTD) return is 4.32% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Armata Pharmaceuticals, Inc. 52-week low Share Price is USD 3.30 on June 20, 2025, which is 70.98% above the current Share Price.
Armata Pharmaceuticals, Inc. 52-week low Share Price is USD 0.90 on June 20, 2025, which is -53.16% below the current Share Price.
Armata Pharmaceuticals, Inc. average Share Price for the last 52 weeks is USD 2.13.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NYSE American: ARMP

Armata Pharmaceuticals, Inc.

CEO	Dr. Deborah L. Birx M.D.
IPO Date	May 20, 1994
Location	United States
Headquarters	4503 Glencoe Avenue
Employees	60
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.